Jim Cramer offered his latest investment advice, highlighting specific stock recommendations like Wells Fargo, Nokia, and Broadcom, and shared his outlook on the market's "remarkable" rally and the upcoming big earnings week. He also discussed strategic moves for his Investing Club.

Gilead Sciences has once again extended its tender offer to acquire Arcellx.

Gilead Sciences (GILD) announced its intention to acquire Tubulis for $5 billion, a strategic move to strengthen its oncology drug pipeline.

An analysis explores whether Gilead Sciences (GILD) qualifies as a top low-volatility blue-chip stock for current investment portfolios.

Galapagos NV announced it has signed an agreement with Gilead Sciences concerning assets related to Ouro Medicines. The details of the agreement were not immediately specified.

Gilead Sciences has announced its intention to acquire Ouro Medicines in a deal valued at $2.18 billion, aiming to expand its pipeline of treatments for inflammatory diseases.

Gilead Sciences has announced its acquisition of Ouro Medicines and a subsequent collaboration with Galapagos on the newly purchased assets, as reported by the Wall Street Journal.

A report highlights notable healthcare headlines for the week, focusing on developments related to pharmaceutical companies Viatris, Novo Nordisk, and Gilead Sciences.

Gilead Sciences has announced a $7.8 billion payment to take full control of a promising multiple myeloma therapy, expanding its oncology portfolio.

Gilead Sciences has announced its acquisition of Arcellx in a deal valued at up to $7.8 billion.

Barclays has adopted a neutral stance on Gilead Sciences, acknowledging its strategic refocus but maintaining a cautious outlook.

Citi has increased its price target for Gilead Sciences (GILD) in anticipation of the company's upcoming Q1 Biopharma preview.

Morgan Stanley has revised its outlook for Gilead Sciences, citing updated biopharma models that suggest a more positive financial trajectory for the company.

Seeking Alpha analysts have released their latest stock recommendations, including upgrades and downgrades for companies such as Palantir (PLTR), Rivian (RIVN), Gilead Sciences (GILD), and Intel (INTC). Additionally, unusual put options volume for Intel (INTC) has been observed, interpreted by some as a bullish signal for the company.

Gilead Sciences has provided details on its deals with Tubulis, Ouro, and Arcellx, which are seen as pipeline catalysts, with further updates expected by 2026.

Investors are anticipating several key earnings reports from major companies, including PG&E Corporation, Procter & Gamble, CenterPoint Energy, and Gilead Sciences, that are set to be released after the market closes on Thursday.

Gilead Sciences, Inc. (GILD) is seeing its growth prospects bolstered by recent analyst upgrades, indicating positive sentiment in the market.

Gilead Sciences' experimental HIV treatment has demonstrated low discontinuation rates in recent studies, indicating potential for improved patient adherence.

Gilead Sciences has announced its intention to acquire Arcellx, a developer of cancer therapies, in a deal valued at up to $7.8 billion.

Gilead Sciences has announced its intention to acquire Arcellx in a deal valued at $7.8 billion, expanding its portfolio in the biotechnology sector.

Analysts are sharing their opinions and insights on Gilead Sciences (GILD) following its recent earnings report.

Morgan Stanley has adjusted its outlook for Gilead Sciences, Inc. in anticipation of the company's first-quarter earnings report.

Gilead Sciences is projecting a $107 million headwind to its first-quarter earnings, attributed to recent research and development deals.

Analysts have released their latest stock recommendations, including upgrades and downgrades for companies such as Palantir, Rivian, Gilead Sciences, and Intel, alongside a specific buy prediction for QuantumScape (QS) stock before April 22, and analysis on Tesla's recent pullback.

Gilead Sciences announced its intention to acquire Tubulis, a company specializing in antibody-drug conjugates (ADCs), in a deal valued at $5 billion, expanding its oncology pipeline.

Galapagos NV and Gilead Sciences have entered into an agreement concerning the acquisition of Ouro Medicines, signaling a new development in the pharmaceutical sector.

US biopharmaceutical company Gilead Sciences has agreed to acquire Ouro Medicines for up to US$2.18 billion, gaining rights to an antibody-based medicine for autoimmune diseases licensed from China’s Keymed Biosciences.

Gilead Sciences has announced plans to acquire Ouro Medicines and will subsequently collaborate with Galapagos on the assets obtained through the purchase.

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Oruka Therapeutics (ORKA), Radnet (RDNT) and Gilead Sciences (GILD)  The Globe and Mail

Gilead Sciences has announced the acquisition of Arcellx, a company specializing in CAR-T cell therapies, in a deal valued at $7.8 billion.

Gilead Sciences announced its plan to acquire cancer drug developer Arcellx in a deal valued at up to $7.8 billion, as pharmaceutical groups continue to acquire smaller biotech firms.

Gilead Sciences has announced its intention to acquire Arcellx in a deal valued at $7.8 billion, expanding its presence in the biotechnology sector.